3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
134
Carcinoma, Non-Small-Cell Lung
133
Prostatic Neoplasms
87
Lung Neoplasms
43
Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
30
Neoplasm Metastasis
29
Stomach Neoplasms
26
Head and Neck Neoplasms
24
Esophageal Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Pancreatic Neoplasms
17
Ovarian Neoplasms
16
Urinary Bladder Neoplasms
13
Sarcoma
12
Adenocarcinoma of Lung
9
Triple Negative Breast Neoplasms
8
Fallopian Tube Neoplasms
8
Carcinoma, Transitional Cell
8
Carcinoma, Ovarian Epithelial
8
Adenocarcinoma Of Esophagus
7
Recurrence
6
Inflammatory Breast Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma
5
Breast Neoplasms, Male
5
Adenocarcinoma, Bronchiolo-Alveolar
5
Laryngeal Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumors
4
Interventions
vofatamab
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
pembrolizumab
1
Standard of Care
1
Mitomycin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urologic Diseases
×
Docetaxel
×
Clear all
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts